Method for Treating Cancer Using Immune Checkpoint Inhibitor

By detecting immune checkpoint proteins and lymphoid/myeloid lineage-specific proteins in CTCs using a high-density microchip and fluorescence labeling, the method addresses the limitations of tissue biopsies, enabling accurate patient selection for immune checkpoint inhibitors with comparable efficacy.

JP7763854B2Active Publication Date: 2025-11-04CYTOGEN CO LTD
5 Cites 0 Cited by

Patent Information

Application Number
JP2023562469
Authority / Receiving Office
JP · JP
Patent Type
Patents
Current Assignee / Owner
Priority Date
2021-04-12
Filing Date
2022-04-08
Publication Date
2025-11-04
Estimated Expiration
2042-04-08

AI Technical Summary

Technical Problem

Current methods for determining patient eligibility for immune checkpoint inhibitors are invasive, painful, and unreliable due to changing protein expression profiles in tumor microenvironments, limiting treatment efficacy to 20-30% and requiring tissue biopsies that are difficult to perform repeatedly.

Method used

A method involving the detection of immune checkpoint proteins and lymphoid or myeloid lineage-specific proteins in circulating tumor cells (CTCs) from blood samples, using a high-density microchip and fluorescence labeling to identify patients eligible for immune checkpoint inhibitor treatment.

Benefits of technology

This method allows for accurate selection of patients for immune checkpoint inhibitor treatment, achieving similar treatment effects as tissue biopsies without invasiveness, with a success rate comparable to traditional methods.

✦ Generated by Eureka AI based on patent content.
Patent Text Reader

Abstract

The present invention relates to a method for treating cancer using an immune checkpoint inhibitor, more specifically, a method for confirming the expression of an immune checkpoint protein and a lymphatic or myeloid cell-specific protein from circulating tumor cells isolated from blood, selecting a patient who is confirmed to have positive expression of an immune checkpoint protein and a lymphatic or myeloid cell-specific protein as a patient to whom an immune anticancer drug can be applied, and administering an immune checkpoint inhibitor to the patient to treat cancer. The method for treating cancer using circulating tumor cells according to the present invention selects patients by simultaneously confirming the expression of an immune checkpoint protein and a lymphatic or myeloid cell-specific protein in a liquid biopsy, and therefore has a remarkably excellent degree of agreement with a tissue test and is highly commercially applicable, and is therefore useful for the diagnosis and treatment of cancer.
Need to check novelty before this filing date? Find Prior Art